Germline Testing for Predisposition to Myeloid Malignancies
Start Date
11/10/2025
Completion Date
4/1/2033
Summary
The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.
Detailed Description
This prospective, single arm study aims to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies. Investigators hope to learn how to best incorporate routine genetic testing in clinical care for participants with blood cancers, regardless of personal or family history of blood cancer. The research study procedures include screening for eligibility, in-clinic visits, questionnaires, and punch skin biopsies. It is expected that about 200 people will take part in this research study. The laboratory sponsor of this protocol is Broad Clinical Laboratory.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
MyeloGen Gene Panel
Conditions
Locations
Dana-Farber Cancer Institute
Boston, Massachusetts 02215
United States